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INTRODUCTION
Platelets play a key role in arterial thrombosis (1) and acute
vascular events (2, 3).  Activated platelets translocate and secrete
P-selectin from their alpha granule (4-6). Once exposed on
activated platelets, P-selectin on platelets interacts with leuko-
cytes and then induces inflammatory signals to potentiate vas-
cular injury (7, 8). In several experimental studies (9, 10), early
manipulation for P-selectin attenuates the reperfusion injury
and infarction volume in ischemic rat brain, suggesting that
P-selectin on platelets may implicate in progression of ischemic
stroke. Actually, it has been reported that the surface expression
of P-selectin on platelets is significantly increased in patients
with acute ischemic stroke compared to normal control (11,
12). However, most previous studies focused on the differences
of P-selectin expression on platelets according to the subtypes
of ischemic stroke and did not serially evaluate the relationship
between their changes and clinical severity of ischemic stroke.
Therefore, in this study, we serially measured the extent of
P-selectin on the surface of platelets in acute ischemic stroke
to elucidate its relationship with severity of ischemic stroke.
PATIENTS AND METHODS
Patients
Forty-five ischemic stroke patients evaluated within 24 hr
of stroke onset. Excluded from the study were patients (1) who
have been previously taking anti-platelet agents; (2) who had
autoimmune, hepatic, renal, or cancerous diseases; (3) who had
a significant infection (leukocytes counts >11,000) or history
of recent infection (<2 weeks). The diagnosis was established
based on medical history, clinical examination, and result of
brain MRI and MRA scan. In patients with acute ischemic
stroke, the following diagnostic tests were performed; com-
plete blood counts, blood chemistry, EKG, chest radiography,
transthoracic cardiac echocardiography, transcranial cranial
Doppler (TCD), and carotid duplex sonography. As a result,
twenty-five patients had a large artery atherosclerotic infarction
(LAA) related with major arteries (internal carotid, vertebro-
basilar, or middle cerebral artery et al.) stenosis (>50%) which
explains the localization of stroke, 13 patients lacunar infarc-
tion and 7 patient cardio-embolic infarction. The clinical
severity of acute ischemic stroke was evaluated upon admission
(within 24 hr), after 72 hr, and after 7 days of stroke onset
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Surface Expression of P-selectin on Platelets Is Related with Clinical
Worsening in Acute Ischemic Stroke
Platelet activation has a critical role in arterial disorders. In this study, we showed
that the upregulation of P-selectin expression on platelets was related with clinical
worsening in acute ischemic stroke. We serially (within 24 hr, at 72 hr, and 7 days)
measured the expression of P-selectin on platelets in patients with acute ischemic
stroke (n=45) and investigated the correlation between their extents and clinical
severity of ischemic stroke. A significant relationship between the P-selectin expres-
sions and National Institute of Health Stroke Scale (NIHSS) was observed at 72 hr
and 7 days after ischemic stroke onset. Patients with clinical deterioration showed
significantly increased expression of P-selectin on platelets as compared to those
without deterioration. These results suggest that the P-selectin expression on
platelets may contribute to the aggravation of clinical course in acute ischemic
stroke. Thus, adequate manipulation of activated platelets is an important thera-
peutic strategy in acute ischemic stroke.    
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using the National Institutes of Health Stroke Scale (NIHSS)
(13). Clinical deterioration was defined as an increase by ≥4
points on NIHSS during the 7 days of observation compared
with the scores at initial work-up. All patients received intra-
venous heparin or subcutaneous heparinoid during this obser-
vation period. 
Twenty-four normal subjects were recruited as a control
group in which no evidence of large vessel atherosclerosis, clin-
ical history of vascular events, and vascular risk factors were
found. 
Blood sampling
Peripheral venous blood was taken at 3 time points; within
24 hr, at 72 hr, and at 7 days after ischemic stroke onset. The
samples were anticoagulated with 3.2% sodium citrate. All
patients or relatives gave informed consent. Among the 45
ischemic stroke patients in this study, 1 patient died and 2
patients were discharged within 48 hr. 
Preparation of whole blood for flow cytometry
The citrated whole blood samples were diluted at 6 folds
in 30  L of HEPES buffer (137 mmol/L NaCl, 2.7 mmol/L
KCl, 20 mmol/L HEPES, 1 mg/mL bovine serum albumin, 3.3
mmol/L NaH2PO4, pH 7.4). The population of platelets was
detected by using phycoerythrin (PE)-conjugated anti-CD42a
(Pharmingen, SanDiego, U.S.A.). A 5- L fluorescein isothio-
cyanate (FITC)-conjugated P-selectin (Pharmingen, SanDigo,
U.S.A.) monoclonal antibody was used for surface staining to
detect the activated platelets. After careful mixing and incu-
bation for 15 min at room temperature, 2.5 mL of HEPES
buffer containing 0.2% formaldehyde was added.
The stained platelets were analyzed by FACscan (EPICS XL,
Coulter Electronics, Miami, U.S.A.). The assay that we used
showed reproducible results and has been verified in other
clinical studies (14, 15). The recognition of platelet popula-
tion was found to be ≥99% for platelets-specific CD42a anti-
gen. The extent of antibody binding was expressed as the mean
fluorescence intensity (MFI) of total platelet population and
was used as a quantitative measure for glycoprotein surface
expression.
Statistical analysis
All data were presented as mean±standard deviation (SD).
Statistical analysis was performed by using the SAS program.
Statistical intergroup difference was examined with the chi-
square and Fisher’s exact test for categorical variables. Con-
tinuous variables were compared with t-test or ANOVA. To
compare the platelet activation markers at 3 different time
points, independent sample t-test was performed. To examine
the correlation between the extent of P-selectin and NIHSS
scores, Pearson’s correlation coefficient was used. p<0.05 was
considered statistically significant.  
RESULTS
Platelet activation in acute ischemic stroke
Patient characteristics, including risk factors, and laboratory
data taken on admission day are shown in Table 1. Forty-five
Number of patients 9 31
Male (%) 6 (66.6) 14 (45.1)
Age (yr) 56.9±9.2 64.9±11.3
NIHSS 12.0±9.4 8.4±3.9
Hypertension (%) 2 (22.2) 22 (70.9)
Diabetes mellitus (%) 2 (22.2) 8 (25.8)
HbA1c 8.4±0.5 8.8±1.2
Smoking (%) 6 (66.6) 13 (41.9)
Old myocardial ischemia 2 (22.2) 2 (6.4)
Leukocytes count (/ L) 9,300±3,200* 6,700±1,900
Platelets count (×103/ L) 226±72 207±54
Total cholesterol (mg/dL) 236±66 192±37
LDL cholesterol (mg/dL) 143±51 118±29
Triglyceride (mg/dL) 150±71 122±134
P-selectin (MFI) 110.7±39.5 103.7±33.9
*p<0.05 versus non-deterioration group.
LAA- large artery atherosclerotic infarction. NIHSS, National Institute of
Health Stroke Scale. MFI, mean fluorescence intensity.
Clinical 
deterioration
Non-deterioration
Table 2. Comparison of basic characteristics and the extents
of P-selectin on platelets in patients with and without clinical
deterioration
Number of patients 45 24
Male (%) 22 (48.9) 12 (50)
Age (yr) 64.3±11.5 61.7±14.9
Hypertension (%) 25 (56) -
Diabetes mellitus (%) 11 (24) -
HbA1c 8.2±1.8 -
Smoking (%) 19 (42) -
Old myocardial ischemia 5 (11) -
Leukocytes count (/ L) 7,270±2,440 6,520±1,700
Platelets count (×10
3/ L) 212±58 231±58
Total cholesterol (mg/dL) 203±47 180±40
LDL cholesterol (mg/dL) 123±35* 89±33
Triglyceride (mg/dL) 132±120 89±39
P-selectin (MFI)    initial 24 hr 108.2±38.3* 75.3±9.1
at 72 hr 103.2±39.5*
at 7 days 101.7±41.3*
*p<0.01 versus normal subjects.
MFI, mean fluorescence intensity.
Acute ischemic
stroke
Normal subjects
Table 1. Characteristics and the extent of P-selectin on platelets
in patients and normal subjects P-Selectin and Clinical Worsening of Ischemic Stroke 813
patients with acute ischemic stroke (22 men and 23 women)
aged 31 to 83 yr (64.3±11.5) and normal subjects (n=24; 12
men and 12 women) aged 27 to 89 yr (61.7±14.9). During
the initial 24 hr of onset, the surface expressions of P-selectin
on platelets were significantly elevated in acute ischemic stroke
patients compared to normal subjects. This elevation was
sustained throughout the observation period of seven days in
patients with acute ischemic stroke (Table 1).
P-selectin and clinical course of ischemic stroke
The mean NIHSS score was 10.2±6.2 at initial 24 hr,
9.0±7.0 after 72 hr, and 8.6±8.6 after 7 days of acute
ischemic stroke. No significant correlation was observed
between the extent of P-selectin on platelet and the NIHSS
at the initial 24 hr. However, the surface expression of P-
selectin correlated well with the NIHSS stroke scale after 72
hr. It became more prominent after 7 days (Fig. 1).
Among the 42 ischemic stroke patients who were evaluated
for the complete observation period, 31 patients experienced
improvement or remained stable, and 11 experienced clinical
deterioration (LAA 7). Two patients with clinical deterioration
had hemorrhagic transformation. To investigate the possible
relevance of platelet activation to the clinical deterioration,
data obtained from the clinical deterioration group (n=9) was
compared with those from the non-deterioration group (n=31).
Table 2 showed main baseline characteristics between clinical-
and non-deterioration groups. The leukocyte count was sig-
nificantly higher in deterioration group compared to non-
deterioration group (Table 2). Surface expressions of P-selectin
on platelets were statistically increased in patients with clini-
cal deterioration than in the non-deterioration group after
72 hr and after 7 day compared to their counterpart (Fig. 2A).
Because most of the acute ischemic stroke showing clinical
deterioration belonged to the LAA group, the extents of P-
selectin on platelets within LAA were re-analyzed. Table 3
summarizes the clinical and laboratory data between non- and
deterioration group. All of clinical and laboratory findings
showed no differences between two groups at initial 24 hr,
except leukocytes count (Table 3). A significant increase of
P-selectin expressions was observed after 72 hr and 7 days in
the group that experienced clinical deterioration (Fig. 2B).
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Fig. 1. The correlation between NIHSS and platelet activation. The
surface expression of P-selectin was significantly correlated with
NIHSS at 72 hr and days after ischemic stroke.
NIHSS, National Institue of Stroke Scale.
MFI, mean fluorescence intensity.
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DISCUSSION
In this study, we measured the P-selectin expression on
platelets by using whole blood flow cytometry. The advan-
tages of this method include not being influenced by artificial
platelet activation of centrifugation and directly reflecting the
platelet activation in vivo (16). Therefore it has been known
as an effective tool to screen the platelet function in clinical
setting. 
In this study, we used heparin or heparinoid in patients with
acute ischemic stroke for initial 7 days. Previous reports (17, 18)
showed that heparin or heparinoid could downregulate cir-
culating level of P-selectin. In spite of this effect, our results
revealed that surface expressions of P-selectin on platelets increased
more significantly in patients with acute ischemia than in
normal subjects, which is consistent with the results from
the previous studies (11, 12). In this study the expression of P-
selectin on platelets sustained during the 7 days after onset of
ischemic stroke. Also, the surface expressions of P-selectin on
platelets were correlated well with the clinical severity and
significantly increased in patients with clinical deterioration
at 72 hr and 7 days after ischemic insult. Thus, it is suspected
that the P-selectin on platelets has important role in progres-
sion of ischemic stroke during 7 days. 
It has been known that several different mechanisms are
involved in the clinical deterioration of ischemic stroke. Among
them, the inflammatory processes are important in progression
of ischemic stroke. During the early stage of ischemic stroke,
massive accumulation of leukocytes occurs at the ischemic areas
and potentiates the ischemic neuronal injury by microvascular
obstruction and by release of oxygen radicals and a cytolytic
enzyme (19). In addition, various pro-inflammatory cytokines,
chemokines, and adhesion molecules influence these processes
(20-22). Interleukin (IL)-8 is a member of C-X-C chemokines
(23), recruiting leukocytes, and was detected in brain tissues
and blood during the early ischemia-reperfusion injury and
finally contributed to the formation of brain edema in an ani-
mal study (24, 25). In line with the above mentioned facts,
the leukocytes count could predict the clinical outcome after
ischemic stroke (26, 27) and was significantly higher in the
clinical deterioration group than in the non-deterioration
group in our study. These inflammatory processes of ischemic
events may be reciprocally affected by activated platelets (1, 7,
and 8). Particularly, P-selectin on activated platelets interacts
with P-selectin glycoprotein ligand (PSGL)-1 on leukocytes
Number of patients 7 15
Male (%) 5 (71.4) 9 (60)
Age (yr) 57.1±10.6 62.9±8.3
NIHSS 13.3±10.0 9.1±2.9
Hypertension (%) 1 (14.3) 9 (60)
Diabetes mellitus (%) 2 (28.6) 3 (20)
HbA1c 8.4±0.5 8.2±0.5
Smoking (%) 4 (57.1) 8 (53.3)
Old myocardial ischemia (%) 2 (28.6) 2 (13.3)
Leukocytes count (/ L) 9,900±3,200* 7,400±1,800
Platelets count (×103/ L) 215±67 222±62
Total cholesterol (mg/dL) 251±67 192±32
LDL cholesterol (mg/dL) 150±56 117±27
Triglyceride (mg/dL) 154±70 98±34
P-selectin (MFI) 120.0±39.8 120.97±41.1
*p<0.05 versus non-deterioration group. LAA- large artery atheroscle-
rotic infarction. NIHSS, National Institute of Health Stroke Scale. MFI,
mean fluorescence intensity.
Clinical 
deterioration
Non-deterioration
Table 3. Comparison of basic characteristics and the extent of
P-selectin on platelets in large artery atherosclerotic infarition
patients with and without clinical deterioration 
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Fig. 2. Comparison of sequential changes of P-selectin on platelets in patients with and without deterioration. (A) Whole population of
ischemic stroke (n=40). (B) Patients with large artery atherosclerotic infarction (n=22). MFI, mean fluorescence intensity. *p<0.05 versus
non-deterioration group.
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and then secretes IL-8 and monocyte chemotactic protein
(MCP)-1 to accumulate leukocytes and to aggravate the is-
chemic neuronal injury (28). In animal studies, P-selectin
accumulates neutrophils in the ischemic brain and eventually
leads to brain edema (9, 10). Therefore, it is hypothesized that
overexpression of P-selectin on platelets may aggravate the
progress of ischemic stroke. This hypothesis is partly supported
by the observation that the increased expressions of P-selectin
in platelets might predict the poor clinical outcome in acute
coronary syndrome (29, 30). In the present study, we investi-
gated the correlation between P-selectin and clinical deteri-
oration in ischemic stroke. Therefore, we cannot clearly define
whether the upregulation of P-selectin on platelets contribute
to the development of clinical deterioration of ischemic stroke
or simply represents a marker of the progression of brain
ischemia. In an experimental study showing a causal relation-
ship (31), animals that failed to express the P-selectin exhibit-
ed smaller infarcts and improved survival compared with
control animals, suggesting that the P-selectin may be a criti-
cal factor for the provocation of neurological deterioration
after ischemic stroke. However, it is still controversial (32)
whether the gene deletion of P-selectin is beneficial or not
in focal brain ischemia. Further studies are underway to clarify
the causal relationship between P-selectin and clinical course
of ischemic stroke. 
In this study, no significant relationship was observed be-
tween the extent of P-selectin and clinical severity of ischemic
stroke within 24 hr of ischemic onset. Although, we cannot
exactly explain the cause, their extents within 24 hr of stroke
onset may be revealed the differences according to the subtypes
of ischemic stroke. Previous studies showed that the extent of
P-selectin expression on platelets was significantly increased
in atherosclerotic ischemic stroke than in other subtypes within
24 hr (11, 12).
Taken together, our data suggest that upregulation of P-
selectin on platelets is related with the clinical course of acute
ischemic stroke. Therefore, a therapeutic strategy to modulate
the signal transduction through the membrane-bound P-
selectin in activated platelets may help to prevent the progres-
sion and complication of acute ischemic stroke.
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